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lioblastoma multiforme (GBM) is the most
common type of primary malignant brain
tumor and presents a major challenge to the
neuro-oncology community.1 The overall prognosis
is poor with best standard care, with as few as 8%-
20% of patients surviving 2 years following diagno-
sis2 and less than 5% surviving beyond 5 years.1 GBM
is characterized by infiltrative growth and invariably
recurs even with aggressive initial therapy.3,4 For
patients with recurrent GBM, treatment options are
limited, and there is no clear standard of care.3,5 In
2009, bevacizumab received accelerated US Food
and Drug Administration (FDA) approval for recur-
rent GBM based on phase II trials showing good
response rates and progression-free survival com-
pared with historical controls.5–8 However, about
40% to 60% of treated patients with recurrent GBM
are unresponsive to bevacizumab, while others
experience serious adverse events,3,5,9 and allS25-S34 S25
A.A. Kanner et alS26initially responsive patients relapse.5 Hence, there is
a critical need for additional treatments for patients
with recurrent GBM.
The NovoTTF-100A System (Novocure Ltd., Haifa,
Israel) is a novel antimitotic cancer treatment for
recurrent GBM. The NovoTTF-100A System consists
of a portable device that delivers alternating low-
intensity, intermediate-frequency, tumor-treating
electric fields (TTFields) to the patients’ brain via
noninvasive transducer arrays attached to the
scalp.10 TTFields have been shown to inhibit the
growth and induce the death of a wide range of
tumor cells in vitro and in animal tumor models.11,12
More specifically, by disrupting mitotic spindle for-
mation during metaphase-to-anaphase transition and
by causing dielectrophoretic movement of charged
or polar molecules and organelles during anaphase
and telophase, TTFields promote selective destruc-
tion of GBM (or other rapidly dividing) cells via
mitotic arrest and apoptosis.13,14 Preclinical studies
also suggest that combining TTFields with chemo-
therapy may enhance chemotherapeutic efficacy
without increasing toxicity.15,16 NovoTTF Therapy
approval was based on pivotal phase III trial
results.17 In this trial, NovoTTF Therapy demon-
strated equivalent overall survival (OS) as compared
to best physician’s choice chemotherapy in patients
with recurrent GBM, with significantly fewer serious
adverse events and significantly better quality of
life.17
Given the mechanism of action of TTFields—
which, unlike drug therapy, does not include a
half-life and applies only during use—we hypothe-
sized superior efficacy would be observed with the
NovoTTF-100A System in an analysis of the phase III
data that focused on the “as-treated” or modified
intention-to-treat (mITT) population rather than on
the ITT population examined in the original report.
The mITT population included all NovoTTF Therapy
patients receiving at least one predefined treatment
course (28 days), and all chemotherapy patients
receiving at least one course of chemotherapy. To
evaluate this hypothesis, we performed a post hoc
analysis of the pivotal phase III trial data to inves-
tigate the impact of at least one full course of
NovoTTF Therapy or chemotherapy on OS in
patients. We also examined the correlation between
NovoTTF Therapy compliance and OS.
In addition, we performed a number of post hoc
analyses to compare OS rates in subgroups of
patients in the ITT population who were treated
with NovoTTF Therapy or chemotherapy. Of partic-
ular interest was the subgroup consisting of patients
who had previously failed bevacizumab therapy.
More generally, there have been recent reports of
very extended and ongoing survival of a subset of
patients treated with NovoTTF Therapy,18,19 and thepost hoc analyses here represent an attempt to
identify patient- or disease-related characteristics
predictive of response to NovoTTF Therapy.
A recent post hoc study by Wong and coworkers20
of the pivotal phase III trial data identified prior low-
grade histology and lower cumulative dexametha-
sone dose as important factors distinguishing
NovoTTF Therapy responders from nonresponders
among recurrent GBM patients. However, these
variables did not distinguish response to chemo-
therapy, though the overall number of patients in
this analysis was low.MATERIALS AND METHODS
Patient Selection and Study Design
General details of the pivotal phase III trial of the
NovoTTF-100A System in recurrent GBM have pre-
viously been reported.17 A CONSORT (Consolidated
Standards of Reporting Trials) diagram of the study
appears as Figure 1,20 and includes a breakdown of
the respective numbers of patients in the ITT and
mITT populations for the survival analysis.
Briefly, between September 2006 and May 2009,
adult patients with histologically confirmed and
prior treated GBM and radiologically confirmed dis-
ease recurrence or progression were randomized in
a 1:1 ratio to receive either NovoTTF Therapy
(monotherapy) or chemotherapy. Prior therapy had
to include radiotherapy, with or without concom-
itant temozolomide. There was no limit on number
or type of prior therapies or recurrences. Patients
with an implanted electronic medical device or with
an supratentorial tumor location were excluded
from enrollment because of a physical limitation:
the majority of the electric fields delivered from the
transducer arrays on the scalp distributed to the
supreatentorial part of the brain. For patients
assigned to the NovoTTF Therapy group, treatment
was self-administered and continuous while they
maintained normal daily activity. Patients assigned
to the chemotherapy group received a chemother-
apy regimen of the local investigator’s choice, based
on local practice and prior treatment exposure.17
One cycle of NovoTTF-100A System treatment con-
sisted of continuous treatment for 28 days or
4 weeks, while one cycle of chemotherapy consisted
of delivery of the drug until recovery of blood counts
or side effects, which usually required 4 to 6 weeks.
Statistical Analysis
The principal endpoint for the subgroup analyses
was OS, computed from the day of randomization
until event (death) or censored at the last follow-up
according to the Kaplan-Meier method. All survival
comparisons between groups were performed using
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) ﬂow diagram and modiﬁed intention-to-treat (mITT)
and ITT populations.
NovoTTF-100A system versus BPC chemotherapy S27a two-sided log-rank (Mantel-Cox) test with α of 0.05.
Unless otherwise stated, all analyses were performed
using the ITT population (all randomized patients
regardless of whether they received any treatment).
A Cox proportional hazards model (CPHM) was
initially used to identify subgroups warranting fur-
ther evaluation in post hoc analyses. The CPHM used
a direct model including all baseline patient and
disease characteristics simultaneously. Only charac-
teristics that independently met a p value of 0.15 or
below were considered significant. Based on the
results of the CPHM, treatment-related effects on OS
were analyzed for the following specific patient
subgroups: age (r60 years or460 years), Karnof-
sky performance status (KPS;Z80 oro80), surgery
status (biopsy only or any resective surgery), GBM
type (secondary [prior low-grade glioma] or pri-
mary), tumor size (Z18 cm2 oro18 cm2), and
bevacizumab failure versus non-bevacizumab failure
(prior to enrollment). Treatment-related effects onOS were also analyzed for reoperation status (yes or
no) and maximal compliance (Z75% oro75% of
treatment time [hours/day use]).
Log-rank OS comparisons of the ITT population
also were performed for NovoTTF Therapy versus
bevacizumab and for NovoTTF Therapy versus che-
motherapy (excluding bevacizumab). Differences in
OS between NovoTTF Therapy and chemotherapy
(including bevacizumab) also were analyzed for the
mITT population. The mITT population included all
NovoTTF Therapy patients who received at least
1 course of treatment (28 days), and all patients
randomized to the chemotherapy group who
received at least one course of any chemotherapy
protocol, including bevacizumab alone or in combi-
nation with cytotoxic chemotherapy.
The relationship between NovoTTF Therapy com-
pliance (calculated as percentage use per day) and
mean OS was compared using the Spearman rank
correlation coefficient for 40%–59%, 60%–79%, and
A.A. Kanner et alS2880%–100% compliance. The portable device has an
internal log file that allows the calculation of patient
compliance. Treatment time evaluation was calcu-
lated from the first day of a patient’s treatment until
the last. When a patient did not complete a full
28-day course, the percentage reported was the total
number of days treatment was received. This per-
centage reflected patient compliance with treatment
and represented the average daily “dose” of TTFields
received. Trend analysis of the relationship between
compliance and OS was examined using Kaplan-
Meier curves for compliance subgroups and the log-
rank test for trend.RESULTS
Patients
The ITT and mITT populations for the NovoTTF
Therapy cohort consisted of 120 and 93 patients,
respectively, while the ITT and mITT populations of
the chemotherapy cohort each contained 117
patients. Baseline characteristics of the ITT popula-
tion were previously reported.17 Of note, patient
characteristics were balanced for the two treatment
groups. Eight percent of patients in both the
NovoTTF Therapy group and the active chemother-
apy group had a history of prior lower-grade glioma;
21% of NovoTTF Therapy patients and 15% of active
chemotherapy patients had a biopsy only;480% of
patients failed two or more prior lines of chemo-
therapy; and 19% of NovoTTF Therapy patients and
18% of chemotherapy patients failed prior bevacizu-
mab therapy.17
As-Treated (mITT) Analysis of Median OS
Median OS in patients who received at least one
course of NovoTTF Therapy was significantly longerFigure 2. Kaplan-Meier overall survival for modiﬁed inten
(B) populations with recurrent glioblastoma multiforme treated
chemotherapy in the phase III trial.than in patients who received at least one course of
any active chemotherapy, including patients who
received bevacizumab off-label instead of entering
the study (7.8 v 6.0 months, respectively; hazard
ratio [HR], 0.69; 95% CI, 0.52-0.92; χ2 P ¼ .0093).
The Kaplan-Meier survival curves are shown in
Figure 2.
Compliance
Ninety-two (77%) of the patients in the ITT
population received NovoTTF TherapyZ75% of
the time (median compliance, 86%; range, 41%-
98%). Median OS for NovoTTF Therapy patients with
a monthly compliance rateZ75% (n ¼ 92) was
significantly longer than for patients who received
treatmento75% (n ¼ 28) of the time, 7.7 v
4.5 months, respectively (log-rank P ¼ 0.042). When
the NovoTTF Therapy cohort was further subdivided
into three groups according to extent of compliance
(40%–59%, 60%–79%, or 80%–100% compliance for
each 24-hour period), there were 10 (8%), 33 (28%),
and 77 (64%) patients in each group, respectively. A
Spearman rank correlation test indicated a positive
correlation between treatment compliance and mean
OS (correlation coefficient, 0.175; one-sided P ¼
.030) (Figure 3A). Kaplan-Meier analysis demon-
strated a significant trend for improved median OS
with higher compliance: median OS of 5.8, 6.0, and
7.7 months foro60% (n ¼ 10), 60%–79% (n ¼ 33),
and 80%–99% (n ¼ 77) compliance, respectively (log-
rank test for trend, χ2 P ¼ .039) (Figure 3B).
Subgroup Analyses (ITT population)
Median OS was significantly longer in the
NovoTTF Therapy group than in the chemotherapy
group for patients who had previously failed bevaci-
zumab, had a prior low-grade glioma, had larger
baseline tumor size, and those with higher KPStion-to-treat (mITT) (A) and intention-to-treat (ITT)
with NovoTTF Therapy or BPC (best physician’s choice)
Figure 3. (A) Spearman rank correlation between NovoTTF Therapy compliance and mean overall survival (OS) showed a
correlation coefﬁcient of 0.175 (1-sided P ¼ .030). (B) Kaplan-Meier OS curves stratiﬁed according to compliance. There
was a trend for longer median OS with better compliance, with median OS of 5.8 months foro60% compliance
(n ¼ 10), 6.0 months for 60% to 79% compliance (n ¼ 33), and 7.7 months for 80% to 99% compliance (n ¼ 77)
(log-rank test for trend, χ2 P ¼ .039).
NovoTTF-100A system versus BPC chemotherapy S29(Table 1). First, among patients who had previously
failed bevacizumab prior to enrollment, median OS
of those treated with NovoTTF Therapy was
6.0 months (n ¼ 23) versus 3.3 months (n ¼ 21)
for those treated with chemotherapy (HR, 0.43; 95%
CI, 0.22–0.85; χ2 P ¼ .016). Second, for patients who
had prior low-grade glioma histology, those treated
with NovoTTF Therapy had a median OS of 25.3
months (n ¼ 12) versus 7.7 months (n ¼ 9) for those
who received chemotherapy (HR, 0.31; 95% CI,
0.09–0.99; χ2 P ¼ .049). Third, for patients who
had a baseline tumor size ofZ18 cm2, NovoTTF
Therapy treatment was associated with a median OS
of 5.6 months (n ¼ 39) versus 3.3 months (n ¼ 41)
for those offered chemotherapy (HR, 0.53; 95% CI,
0.32–0.85; χ2 P ¼ .009). Last, for patients with
baseline KPSZ80, subjects treated with NovoTTF
Therapy had a median OS of 7.9 months (n ¼ 83)
versus 6.1 months (n ¼ 77) for those treated with
chemotherapy (HR, 0.71; 95% CI, 0.51–0.99; χ2 P ¼
.045) (Figure 4).
Because we observed a significant difference in
treatment efficacy between the two trial cohorts who
had failed bevacizumab prior to enrollment, we asked
whether there is also a difference in efficacy between
NovoTTF Therapy and chemotherapy. Indeed,
median OS was also significantly longer for patients
who received NovoTTF Therapy than for those who
received bevacizumab for recurrent GBM in the trial
control group, 6.6 months (n ¼ 120) versus
4.9 months (n ¼ 36), respectively (HR, 0.64; 95%
CI, 0.41–0.99; χ2 P ¼ .045), but not for those who
received non-bevacizumab chemotherapy, 6.6 months
(n ¼ 120) versus 6.6 months (n ¼ 84) (HR, 0.92; 95%
CI, 0.68–1.24; χ2 P ¼ .586) (Figure 5). Table 2
provides the baseline characteristics of patients in
the NovoTTF Therapy and bevacizumab groups.Median OS did not significantly differ between
NovoTTF Therapy and chemotherapy in the follow-
ing subgroups (Table 1): non-bevacizumab failures
(6.7 and 7.2 months, respectively; HR, 0.95; 95% CI,
0.70–1.27; χ2 P ¼ .714); patients without prior
history of low-grade glioma (6.6 and 5.8 months,
respectively; HR, 0.95; 95% CI, 0.72–1.26; χ2 P ¼
.744); tumor sizeo18 cm2 (7.3 and 8.3 months,
respectively; HR, 0.99; 95% CI, 0.71–1.37; χ2 P ¼
.941); KPSo80 (4.8 and 5.4 months, respectively;
HR, 1.26; 95% CI, 0.79–2.02; χ2 P ¼ .338); ager60
years (7.4 and 6.2 months, respectively; HR, 0.74;
95% CI, 0.54–1.02; χ2 P ¼ .063); age460 years (4.8
and 5.7 months, respectively; HR, 1.31; 95% CI, 0.78-
2.19; χ2 P ¼ .309); patients who received any
surgery (6.2 and 6.0 months, respectively; HR,
0.99; 95% CI, 0.74-1.33; χ2 P ¼ .959); and patients
who had biopsy only (7.9 and 5.8 months, respec-
tively; HR, 0.54; 95% CI, 0.27-1.09; χ2 P ¼ .085).
Median OS was also similar in both NovoTTF Ther-
apy and chemotherapy patients who underwent re-
operation before randomization (7.4 and 7.4 months,
respectively) and in non-reoperated patients (6.3 and
5.3 months respectively).DISCUSSION
This analysis demonstrates that NovoTTF Ther-
apy, when used as intended in the mITT population
who participated in the phase III trial, is associated
with significantly longer median OS than is BPC
chemotherapy in patients with recurrent GBM. We
found that NovoTTF Therapy was associated with
nearly 2 months longer survival (7.8 v 6.0 months)
and a roughly 30% reduction in risk of death (HR,
0.69; 95% CI, 0.52–0.92; χ2 P ¼ .012) when com-
pared to patients treated with BPC chemotherapy.
Table 1. Subgroup Analyses Showing Overall Survival for NovoTTF Therapy Versus BPC Chemother-
apy Patients in the Intention-To-Treat Population
NovoTTF Therapy Chemotherapy Hazard Ratio (95% CI) Log-Rank P
Prior bevacizumab failure
Patients, n 23 21 — —
Median OS, mo 6.0 3.3 0.43 (0.22-0.85) .0156
Non-bevacizumab failure
Patients, n 97 96 — —
Median OS, mo 6.7 7.2 0.95 (0.71-1.27) .7136
Prior low-grade glioma (secondary recurrent GBM)
Patients, n 12 9 — —
Median OS, mo 25.3 7.7 0.31 (0.09-0.99) .0493
Primary recurrent GBM
Patients, n 108 108 — —
Median OS, mo 6.6 5.8 0.95 (0.72-1.26) .7436
Tumor sizeZ18 cm2
Patients, n 39 41 — —
Median OS, mo 5.6 3.3 0.53 (0.32-0.85) .009
Tumor sizeo18 cm2
Patients, n 81 76 — —
Median OS, mo 7.3 8.3 0.99 (0.71-1.37) .9405
Karnofsky performance statusZ80
Patients, n 83 77 — —
Median OS, mo 7.9 6.1 0.71 (0.51-0.99) .0453
Karnofsky performance statuso80
Patients, n 37 40 — —
Median OS, mo 4.8 5.4 1.26 (0.79-2.02) .3375
NovoTTF-100A System v bevacizumab (as control group recurrent GBM therapy)
Patients, n 120 36 — —
Median OS, mo 6.6 4.9 0.64 (0.41-0.99) .0450
NovoTTF-100A System v best physician’s choice chemotherapy (excluding bevacizumab)
Patients, n 120 81 — —
Median OS, mo 6.6 6.6 0.92 (0.69-1.24) .5860
Ager60 years
Patients, n 85 83 — —
Median OS, mo 7.4 6.2 0.74 (0.54-1.02) .0631
Age460 years
Patients, n 35 81 — —
Median OS, mo 4.8 5.7 1.31 (0.78-2.19) .3087
Biopsy only
Patients, n 25 18 — —
Median OS, mo 7.9 5.8 0.54 (0.27-1.09) .0848
Any surgery
Patients, n 95 99 — —
Median OS, mo 6.2 6.0 0.99 (0.74-1.33) .9590
A.A. Kanner et alS30These data are distinct from the equivalent OS seen
in the ITT population.17 However, the ITT popula-
tion included all randomized patients, many of
whom did not receive a full cycle of NovoTTF
Therapy and hence might not have been the best
population for testing treatment efficacy against
chemotherapy. This is because the anti-tumor effect
from alternating electric fields requires continuous
treatment and disappears when stopped, while thebiological effects of chemotherapy may persist for
4 to 6 weeks after dosing. The requirement of
continuous application of NovoTTF Therapy was
tested in prior models of GBM, which suggested
that a minimum of four weeks of continuous
treatment is required for tumor stasis or shrinkage
(see Vymazal et al in this supplement). Consistent
with the model data, we included in the mITT
analysis patients who received at least one
Figure 4. Kaplan-Meier overall survival (OS) curves stratiﬁed according to patient subgroups in the intention-to-treat
(ITT) population with (A) prior bevacizumab failure, (B) prior low-grade glioma, (C) tumor sizeZ18 cm2, and
(D) Karnofsky performance statusZ80. BPC ¼ best physician’s choice.
NovoTTF-100A system versus BPC chemotherapy S31continuous 28-day cycle of NovoTTF Therapy and
compared them to patients who received chemo-
therapy, which varied depending on the specific
regimen but always consisted of one treatment
cycle, as chemotherapies were administered in an
intermittent fashion. Arguably, the mITT analysisFigure 5. Overall comparison of Kaplan-Meier overall survival
recurrent glioblastoma multiforme treated with NovoTTF Therap
bevacizumab (n ¼ 81) chemotherapy.provided a more accurate comparison of the two
cohorts because they received similar treatment
amounts as intended for the trial. Therefore, while
the reported results for the ITT population estab-
lished similar efficacy between NovoTTF Therapy
and chemotherapy in recurrent glioblastoma, the(OS) curves for intention-to-treat (ITT) population with
y (n ¼ 120) versus (A) bevacizumab (n ¼ 36) or (B) non-
Table 2. Baseline Characteristics of Patients in the NovoTTF Therapy and Bevacizumab-Treated
Subgroup, Respectively (Intention-to-Treat Population)
Characteristic
NovoTTF Therapy
(n ¼ 120)
Bevacizumab
(n ¼ 36)
Male sex, n (%) 92 (77) 24 (67)
Median (range) age, y 54 (24-80) 51 (29-72)
Recurrence number, n (%)
First 11 (9.2) 4 (11.1)
Second 58 (48.3) 18 (50.0)
Third 51 (42.5) 14 (38.9)
Median (range) baseline tumor area, cm2 14.5 (0-64.1) 15.3 (0-64.3)
Previous low-grade histology, n (%) 12 (10) 2 (6)
Prior bevacizumab failure, n (%) 23 (19) 4 (11)
Median (range) Karnofsky performance status 80 (50-100) 80 (50-100)
Resection for recurrence, n (%) 33 (27.5) 9 (25)
Median (range) dexamethasone dose per day, mg 4.7 (0-38) 4.7 (0-21)
A.A. Kanner et alS32present results from the mITT population suggest
NovoTTF Therapy is associated with a better survival
benefit when used as intended.
It should be noted that our mITT comparison is
limited by the post hoc nature of the analysis, as well
as the major difference between the mechanisms of
action of NovoTTF Therapy and of the chemothera-
pies used in the active control arm of the study.
Nevertheless, this post hoc analysis allowed us to
estimate the magnitude of the difference in OS
between the mITT and ITT cohorts treated with
NovoTTF Therapy. This is important because future
trials of this device in recurrent GBM will need to
take into account the effect of early discontinuation
on efficacy outcome by having a larger sample size
or a lead-in phase to test patients for device com-
pliance in the first 28 days. Furthermore, removing
patients who receivedo28 days of NovoTTF Ther-
apy may have inadvertently biased the mITT analysis
in favor of the device because those who did not
complete a full cycle of treatment may have stopped
because of clinical deterioration. Patients in the
control arm who deteriorated at a similar time point
may have already completed a full treatment cycle of
their assigned chemotherapy. Therefore, the true
survival difference between these two groups may
lie between the outcomes of the mITT and ITT
analyses.
There appears to be a relationship between
NovoTTF Therapy compliance and OS. Patients
who had an average monthly treatment compliance
of more than 75%, which is 18 hours per day or
more, had a median OS of 7.7 months, versus
4.5 months for those patients who were compli-
anto75% of the time. Median OS also appeared to
increase in a stepwise fashion with increasing com-
pliance, from 5.8 months with low compliance
(o60%) to 6.0 months with medium compliance(60%–79%) and 7.7 months with high compliance
(80%–99%) (log-rank test for trend, P ¼ .038). The
progressively higher variability from the low- to high-
compliance groups may account for the lower Spear-
man correlation coefficient, but the differences in OS
between these compliance groups are still signifi-
cant. Consistent with the preclinical data, NovoTTF
Therapy exerts its antimitotic effect during the times
it is applied, and, unlike chemotherapies, it does not
have a half-life associated with its mechanism of
action. Therefore, our data support the recom-
mended usage for this device:Z4 weeks at an
average ofZ18 hours a day (75% of each 24-hour
period) for the total number of days.21
It can be argued that patients who were more
compliant with NovoTTF Therapy were in a better
clinical state, which may in turn independently
predict longer survival. However, entry into the trial
required a KPS of 70 or greater, and this level of KPS
would allow the patient to have independent func-
tion and management of the device with a caretaker.
Furthermore, Vymazal and Wong (in this supple-
ment) also demonstrated a relationship between
compliance and radiologic response, suggesting that
the extent of compliance may be viewed as the
treatment dose exerted onto the tumor. Together,
compliance is probably an independent predictor of
longer OS, but future prospective testing in a clinical
trial is necessary to confirm this observation.
The present study also included post hoc analyses
of various patient subpopulations from the phase III
clinical trial. The intent here was to identify patient
subgroups in the ITT population who might be more
responsive to NovoTTF Therapy than active chemo-
therapy. In future studies, these subgroups can be
more rigorously examined in a prespecified fashion,
and with sufficient power, to prospectively detect
treatment-related differences. Recent reports of
NovoTTF-100A system versus BPC chemotherapy S33recurrent GBM patients alive 6 years or more after
beginning NovoTTF Therapy highlight the need to
better identify the clinical characteristics of patients
predictive of a robust response to NovoTTF ther-
apy.18,19 Furthermore, another recent post hoc
analysis of the phase III data found higher propor-
tions of secondary GBM (prior low-grade histology)
and low dexamethasone usage in recurrent GBM
patients who responded to NovoTTF Therapy than
in those who did not.20 The authors suggested that
these as well as other genetic/epigenetic factors
might determine response to Novo TTF Therapy.
The present study identified a number of variables
that need to be confirmed and included in future
clinical trials. These variables include prior low-
grade glioma (or secondary recurrent GBM), tumor
sizeZ18 cm2, KPSZ80, and patients who had
previously failed bevacizumab therapy. Compared
to the rest of the cohort, patients with prior low-
grade gliomas, tumor sizeZ18 cm2, and KPSZ80
may have tumors with slower growth or a location
farther away from neurologically functional areas of
the brain, allowing sufficient time for NovoTTF
Therapy to exert its anti-tumor effect. Those who
have failed prior bevacizumab therapy may already
have an altered immunologic milieu within the
tumor microenvironment, facilitating immunogenic
cell death that was induced by NovoTTF Ther-
apy.22,23 Because our findings are based on univari-
ate analyses of multiple, originally unspecified
subgroups, they should be viewed with caution,
and as hypothesis-generating rather than definitive
conclusions. The limitations of subgroup analyses—
especially when multiple parameters are examined
post hoc, without a prespecified condition or suffi-
cient power to detect differences between groups—
include an increased risk for type I and type
2 errors.24–26
Although bevacizumab has been approved as
treatment for recurrent GBM, some patients with
recurrent GBM are initially unresponsive to bevaci-
zumab, while the rest of initially responsive patients
eventually become refractory over time.3,5 Given this
observation, it is worth noting that our analysis of
patients who had failed bevacizumab therapy dem-
onstrated a significantly longer OS in patients treated
with NovoTTF Therapy than in patients who
received chemotherapy, 6.0 months (n ¼ 23) and
3.3 months (n ¼ 21), respectively. Another analysis,
comparing the entire NovoTTF Therapy cohort with
patients treated with bevacizumab only in the active
control group, showed that OS was significantly
longer with NovoTTF Therapy compared to bevaci-
zumab, 6.6 months (n ¼ 120) and 4.9 months
(n ¼ 36), respectively (P ¼ .045). It is worth noting
that these results are the only published randomized
results on the efficacy of bevacizumab comparedhead-to-head with another active treatment. Further
substantiation of these findings is warranted in a
prospectively designed trial.
In summary, treatment options for recurrent GBM
are limited, and there is no consensus as to best
therapy at time of recurrence.3,5 The NovoTTF-100A
System was recently approved for recurrent GBM
based on phase III trial results that showed equiv-
alent efficacy with better toxicity and quality-of-life
profiles compared with chemotherapy.17 Results
from the present study suggest that, when used as
intended, NovoTTF Therapy provides efficacy supe-
rior to that of chemotherapy in a heterogeneous
population of patients with recurrent GBM. Post hoc
analyses identified subgroups of patients who may
be particularly good candidates for NovoTTF Ther-
apy, pending further confirmatory studies.Acknowledgments
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